Analysis of the coverage of inactivated enterovirus 71 (EV71) vaccine and adverse events following immunization with the EV71 vaccine among children from 2016 to 2019 in Guangzhou

Expert Rev Vaccines. 2021 Jul;20(7):907-918. doi: 10.1080/14760584.2021.1933451. Epub 2021 Jun 7.

Abstract

Background: Since 2016, China has approved the use of inactivated enterovirus 71 (EV71) vaccines produced by three manufacturers. The coverage and safety of different EV71 vaccines need to be evaluated.Research design and methods: The EV71 vaccination and AEFI data were collected from the Guangzhou Children's Vaccination Information Report Management System and the China AEFI Monitoring Information Management System, and the EV71 vaccine coverage rate and the AEFI incidence rate were analyzed.Results: From 2016 to 2019, the number of people who should have been vaccinated in Guangzhou was 2,781,618, and the coverage rates for doses 1 and 2 were 24.71% and 19.44%, respectively. The inoculation rates of vaccines from manufacturers A and B were between 3.03 and 10.46%. The reported incidence of AEFIs was 11.97 per 100,000 (147 cases), with fever (106 cases, 8.63 per 100,000) and allergic rash (59 cases, 4.80 per 100,000) being the most common reactions. There were no differences in the AEFI responses to the EV71 vaccines from the three manufacturers.Conclusion: The EV71 vaccines from the three manufacturers have good safety, but the EV71 vaccine coverage rate is low. It is recommended that vaccine publicity be strengthened and that the vaccine coverage rate in children be increased.

Keywords: Enterovirus 71 inactivated vaccine; abnormal reaction; inoculation rate; safety; vaccination.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Child
  • Enterovirus A, Human*
  • Enterovirus*
  • Humans
  • Immunization
  • Vaccination
  • Vaccines, Inactivated / adverse effects

Substances

  • Vaccines, Inactivated